Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4059 | psychological and sociological interviews Wiki | 0.38 |
| drug2178 | Neuromuscular evaluation Wiki | 0.38 |
| drug1981 | Maximal effort test Wiki | 0.38 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D015673 | Fatigue Syndrome, Chronic NIH | 0.27 |
| D013180 | Sprains and Strains NIH | 0.27 |
| D005221 | Fatigue NIH | 0.22 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D020920 | Dyssomnias NIH | 0.17 |
| D020447 | Parasomnias NIH | 0.15 |
| D001068 | Feeding and Eating Disorders NIH | 0.14 |
| D012598 | Scoliosi NIH | 0.10 |
| D009103 | Multiple Sclerosis NIH | 0.10 |
| D013577 | Syndrome NIH | 0.04 |
| D011014 | Pneumonia NIH | 0.02 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
| D018352 | Coronavirus Infections NIH | 0.01 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0012378 | Fatigue HPO | 0.22 |
| HP:0002090 | Pneumonia HPO | 0.02 |
Navigate: Correlations HPO
There are 7 clinical trials
Chronic fatigue is the most common and debilitating symptom in intensive care unit (ICU) survivors. Indeed, it has been widely reported that patients who stayed in ICU for prolonged periods report a feeling of tiredness for months to years after ICU discharge. This symptom seems particularly pronounced in Covid-19 patients and may affect their quality of life by decreasing their capacity to perform simple tasks of daily life. The aim of the present project is to determine whether deteriorated neuromuscular function (i.e. increased fatigability) is involved in the feeling of fatigue of Covid-19 patients. Because the causes of this feeling are multi-dimensional, a large battery of tests will allow us to better understand the origin of chronic fatigue. A better knowledge of chronic fatigue etiology and its recovery will allow to optimize rehabilitation treatments to shorten the persistence of chronic fatigue and in fine improve life quality.
Description: Level of cortical activation and cortico-spinal excitability measured by transcranial magnetic stimulation
Measure: Neuromuscular function : cortical activity Time: 6 weeks post-dischargeDescription: Peripheral function by electrical nerve stimulation
Measure: Neuromuscular function : Peripheral function Time: 6 weeks post-dischargeDescription: measured by effort test
Measure: Maximal oxygen uptake (VO2max) Time: 6 weeks post-dischargeDescription: measured by actigraphy
Measure: quality of sleep Time: 6 weeks post-dischargeDescription: with Magnetic resonance imaging
Measure: muscle volume Time: 6 weeks post-dischargeDescription: measured by a Phosphorus 31 Nuclear magnetic resonance test
Measure: metabolic fatigue Time: 6 weeks post-dischargeThe purpose of this study is to determine whether sleep disturbances in children aged 7 to 12 during COVID-19 containment are more prevalent in children who received routine psychiatric care before containment compared to children who don't have any psychiatric care.
Description: Sleep quality is assessed in both groups with the Sleep Disturbance Scale for Children (SDSC scale). A score ≥ 45/125 is considered as pathological.
Measure: Comparison of sleep quality during COVID-19 containment between children usually followed in child psychiatry and children without follow-up Time: An average of 1 dayDescription: Child depression is measured using Child Depression Inventory Scale (CDI scale). For each item the score is graded by severity from 0 (normal behavior) to 2 (severe).
Measure: Assessment of child depression in both groups Time: An average of 1 dayDescription: Child anxiety is measured using Revised Children's Manifest Anxiety Scale (RCMAS). For each item, child answer by Yes or No. The total score is interpreted using the correspondence tables in function of sex and age
Measure: Assessment of child anxiety in both groups Time: An average of 1 dayDescription: Sleep quality is assessed with the Sleep Disturbance Scale for Children (SDSC scale). The score obtained is interpreted in function of socio-demographic factors (age, sex, lifestyle, couple status, profession and socio-professional category, education)
Measure: Assessment of the influence of socio-demographic factors on sleep in both groups Time: An average of 1 dayDescription: Sleep quality is assessed with the Sleep Disturbance Scale for Children (SDSC scale). For their parents, sleep quality and anxiety level are measured with a numerical scale between 0 and 10. For sleep quality, 0 correspond to a very poor quality and 10 to a very good quality. For anxiety level, 0 correspond to no anxiety and 10 to a severe anxiety. The score obtained for child is interpreted in function of their parents score.
Measure: Measure of the correlation between child sleep quality and parents sleep quality (anxiety level) in both groups Time: An average of 1 dayDescription: Sleep quality is assessed with the Sleep Disturbance Scale for Children (SDSC scale). The score obtained is interpreted in function of child psychiatry diagnoses coded with Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
Measure: Assessment of sleep disturbance based on psychiatry diagnoses in the group of children usually followed in child psychiatry Time: An average of 1 dayDescription: Child anxiety is measured using Revised Children's Manifest Anxiety Scale (RCMAS). For each item, child answer by Yes or No. The score obtained is interpreted in function of child psychiatry diagnoses coded with Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
Measure: Assessment of child anxiety based on psychiatry diagnoses in the group of children usually followed in child psychiatry Time: An average of 1 dayDescription: Child depression is measured using Child Depression Inventory Scale (CDI scale). For each item the score is graded by severity from 0 (normal behavior) to 2 (severe). The score obtained is interpreted in function of child psychiatry diagnoses coded with Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
Measure: Assessment of child depression based on psychiatry diagnoses in the group of children usually followed in child psychiatry Time: An average of 1 dayThis project is based in the implementation of a combined monitoring system (technological solutions and medical visits) in survivors of the critical illness due to the infectious disease by COVID-19. The main objective of the project is to characterize the Post-Intensive Care Syndrome (PICS) and detect early needs for specific treatment.
Description: Health related quality of live scale. Values are directly transformed in T scores (mean=50; SD=10), with higher scores meaning better outcome.
Measure: Change from baseline Short Form 12 Health Survey (SF12) at 12 month Time: Every month during a 12 months follow-up periodDescription: Measure of independent living skills. Values are from 0 to 8, with higher scores meaning better outcome.
Measure: Change from baseline Lawton & Brody Instrumental activities of daily living scale at 12 months Time: Every month during a 12 months follow-up periodDescription: Self-report measure of cognitive dysfunction. Values are from 0 to 22, with lower scores meaning better outcome.
Measure: Change from baseline Perceived Deficits Questionnaire (PDQ) at 12 months Time: Every month during a 12 months follow-up periodDescription: A self-assessment instrument for detecting states of depression and anxiety in the setting of an hospital medical outpatient. Values are from 0 to 42, with lower scores meaning better outcome.
Measure: Change from baseline Hospital Anxiety and Depression Scale (HADS) at 12 months Time: Every month during a 12 months follow-up periodDescription: Self-report measure of Post Traumatic Stress Disorder (PTSD) symptoms.
Measure: Change from baseline Davidson Trauma Scale (DTS) at 12 months Time: Every month during a 12 months follow-up period. Values are from 0 to 136, with lower scores meaning better outcome.COVID-19 lockdown presents particular challenges for people living with obesity. Indeed during this period, the lifestyle was deeply modified: diet, activity, and sleep behaviours, home office, take care of child, social distancing... All of these modifications may have led to stress and anxiety. It has been previously demonstrated that high perceived stress levels are correlated with high preference for sweet and fat foods . In this context caution would be exercised in obese patients especially those with binge eating disorders. Indeed binge eating disorder is characterized by compulsive overeating or consuming abnormal amounts of food while feeling unable to stop and a loss of control. And one key trigger of binge eating disorder is stress and anxiety. Thus, patients with binge eating disorders may have been more sensitive to the impact of lockdown and thus urgently would require appropriated care management. The main objective is to compare the eating behaviour between obese patients with or without binge eating disorders. The second objective is to compare the weight evolution between the two groups before and after the lockdown. To reach these objectives, the scientific team of the CIO project proposes to contact by phone and e-mail obese patients (with or without binge eating disorders) who have been hospitalized for their obesity disease before the start of the lockdown in the Endocrinology department of the Lyon Hospital. The patients will be asked to fill in several questionnaires (using an online tool) allowing to evaluate their mood, anxiety, eating behaviour, binge eating disorders… during the lockdown. The results of these questionnaires will be compared to those collected during their hospitalisation before the lockdown. The hypothesis is that participants suffering from binge eating disorder will have more sever eating behaviour perturbations as higher level of stress, anxiety, depressive symptoms.
The intensive care unit occupies a particular place in our health care system. The urgency of the clinical situations, the proportion of deaths encountered, and the daily workload is likely to generate suffering among staff. The health crisis linked to SARS-COV-2 is unprecedented and has leads to the unprecedented mobilisation of care providers, particularly in the ICU. Faced with the massive and growing influx of patients, human, therapeutic and material resources are overwhelmed and the teams are faced with an unusually heavy workload in a context of extreme tension. These professionals are thus exposed to a risk of over-investment, in a context of acute and repetitive stress, over an indeterminate period of time combining workload, emotional intensity with specific ethical issues, simultaneously affecting the professional sphere but also the personal and family sphere (confinement, risk of contamination). Now more than ever, the mental health of caregivers is an important concern, as highlighted by the CCNE. Mental health is understood in the way in which the individual responds specifically to work-related suffering by developing individual and collective defensive strategies. Thus, the issue of mental health in the ICU cannot be considered without taking into account the strategies that professionals put in place to combat stress and to contribute or not to the construction and stabilization of the work collective (collaboration, support). Ethical and/or psychological support systems have been set up in most of the establishments involved in the care of Covid-19 patients. However, the adequacy of these systems relative to the needs of professionals during and after the crisis is not yet known. We hypothesize that the psychological and social repercussions of this pandemic as well as the individual and collective strategies deployed by ICU care providers to deal with it will evolve in view of the progression of the crisis but also of the various types of support, particularly psychological and/or ethical, available to them.
Description: This scale integrates generic stressors as well as factors specific to intensive care and crises.
Measure: PS-ICU Scale Score Time: Through study completion, an average of 6 months after the epidemic peakThe primary goal of this research is to study the prevalence of the wearing-off effect and possible risk factors for wearing-off symptoms in patients with multiple sclerosis using ocrelizumab with the use of questionnaires. Furthermore, the goal is to study whether patients receiving extended dosing of ocrelizumab experience more wearing-off symptoms or adverse events in general. Finally, we would like to extend knowledge on wearing-off symptoms in general.
Description: Prevalence of wearing-off symptoms prior to ocrelizumab infusion (yes/no assessed on questionnaires)
Measure: Wearing-off symptoms Time: BaselineCOVID-19 is associated with acute pulmonary and cardiac injury. To better understand the degree and severity of cardiopulmonary injury as well as short and long-term sequelae of COVID-19 infection, this study will perform longitudinal study in patients who had recent known diagnosis of COVID-19.
Description: Inflammatory markers include D-dimer, ferritin, and CRP measurements
Measure: Level of Inflammatory Markers Time: Up to 12 monthsDescription: Disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Scores range from 0 to 100, with higher scores indicating more limitations.
Measure: Score on St. George's Shortness of Breath Questionnaire (SGSQ) Time: Up to 12 monthsDescription: Short form ZBI-12 validated as screening tool in advanced illness including dementia and cancer. Total ZBI-12 score: summation of 12 items (0 to 4 points per item, total score range 0 to 48). The higher the score, the higher the burden.
Measure: Score on Short Form Zarit Burden Interview (ZBI-12) Time: Up to 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports